Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04556773
Title A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AstraZeneca

Her2-receptor negative breast cancer


Fulvestrant + Trastuzumab deruxtecan

Durvalumab + Paclitaxel + Trastuzumab deruxtecan

Capivasertib + Trastuzumab deruxtecan

Capecitabine + Trastuzumab deruxtecan

Anastrozole + Trastuzumab deruxtecan

Age Groups: adult | senior
Covered Countries USA | FRA | CAN | BEL

No variant requirements are available.